This site is intended for healthcare professionals

ESO Journal 1/2020 Slovak edition

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

de Wit R, de Bono J, Sternberg CN, et al.

ESO Journal 1/2020 Slovak edition

BACKGROUND The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.   METHODS We randomly assigned, in a 1:1 ratio, patients...

Zpět

Paediatric News 1/2025

04 | 04 | 2025

Už čoskoro vyjde nové číslo časopisu Paediatric News.

Česká diabetologie 1/2025

01 | 04 | 2025

Pripravujeme prvé tohtoročné číslo časopisu Česká diabetologie.

Onemocnění hltanu a jícnu

28 | 03 | 2025

Práve vyšiel piaty zväzok reedície Albertovej zbierky.




Partneři projektu